13-去乙基-6,12-二脱氧-13-甲基-红霉内酯A | 53428-54-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯类和类似物
• 中文名称: 13-去乙基-6,12-二脱氧-13-甲基-红霉内酯A
• 英文名称: 8,8a-Deoxyoleandolide
• 英文别名: (3R,4S,5R,6S,7S,9R,11R,12S,13R,14R)-4,6,12-trihydroxy-3,5,7,9,11,13,14-heptamethyl-oxacyclotetradecane-2,10-dione
• CAS: 53428-54-9
• 化学式: C₂₀H₃₆O₆
• 分子量: 372.5
• InChiKey: OLPAVFVRSHWADO-KYEFFAPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  26
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Motilide compounds
  申请人：——

  公开号：US20020094962A1

  公开（公告）日：2002-07-18

  The present invention provides novel macrolide compounds of the formulas 1 wherein: R is hydrogen, substituted C 1 -C 10 alkyl, unsubstituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted aryl, unsubstituted aryl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, or unsubstituted alkynylaryl; R 0 is hydroxyl or methoxy; R 1 is selected from the group consisting of hydrogen, hydroxyl, halide, NH 2 , OR 9 , 2 where R 9 is substituted C 1 -C 10 alkyl, unsubstituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted aryl, unsubstituted aryl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, or unsubstituted alkynylaryl, and R 10 and R 11 are each independently hydrogen, substituted C 1 -C 10 alkyl, unsubstituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted aryl, unsubstituted aryl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, or unsubstituted alkynylaryl; R 1 and R 3 are each independently selected from the group consisting of hydrogen, substituted C 1 -C 10 alkyl, unsubstituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted aryl, unsubstituted aryl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, or unsubstituted alkynylaryl, or R 2 and R 3 together form a cycloalkyl or an aryl moiety; R 4 is hydrogen or methyl; R 5 is hydroxyl or oxo; R is hydrogen, hydroxyl, or OR 12 where R 12 is substituted C 1 -C 10 alkyl, unsubstituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, or unsubstituted C 2 -C 10 alkynyl; R 7 is methyl, unsubstituted C 3 -C 10 alkyl, substituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, or unsubstituted alkynylaryl; R 8 is unsubstituted C 1 -C 10 alkyl, substituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, or unsubstituted alkynylaryl; R 13 is hydrogen, unsubstituted C 1 -C 10 alkyl, substituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, or unsubstituted alkynylaryl; R 17 is hydrogen or methyl; x is a single or a double bond; and, Y is hydrogen, substituted C 1 -C 10 alkyl, unsubstituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted aryl, unsubstituted aryl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, unsubstituted alkynylaryl, unsubstituted cladinose, or substituted cladinose.

  本发明提供了具有以下结构的新型大环内酯化合物：其中：R为氢、取代的C1-C10烷基、未取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的芳基、未取代的芳基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基或未取代的炔基芳基；R0为羟基或甲氧基；R1选自氢、羟基、卤素、NH2、OR9、其中R9为取代的C1-C10烷基、未取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的芳基、未取代的芳基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基或未取代的炔基芳基，以及R10和R11分别独立为氢、取代的C1-C10烷基、未取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的芳基、未取代的芳基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基或未取代的炔基芳基；R1和R3各自独立选自氢、取代的C1-C10烷基、未取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的芳基、未取代的芳基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基或未取代的炔基芳基，或R2和R3共同形成环烷基或芳基基团；R4为氢或甲基；R5为羟基或酮基；R为氢、羟基或OR12，其中R12为取代的C1-C10烷基、未取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基或未取代的C2-C10炔基；R7为甲基、未取代的C3-C10烷基、取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基或未取代的炔基芳基；R8为未取代的C1-C10烷基、取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基或未取代的炔基芳基；R13为氢、未取代的C1-C10烷基、取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基或未取代的炔基芳基；R17为氢或甲基；x为单键或双键；Y为氢、取代的C1-C10烷基、未取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的芳基、未取代的芳基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基、未取代的炔基芳基、未取代的克拉迪诺糖苷或取代的克拉迪诺糖苷。
• Production of polyketides
  申请人：——

  公开号：US20030235892A1

  公开（公告）日：2003-12-25

  Recombinant host cells that comprise recombinant DNA expression vectors that drive expression of a product and a precursor for biosynthesis of that product can be used to produce useful products such as polyketides in host cells that do not naturally produce the product or produce the product at low levels due to the absence of the precursor or the presence of the precursor in rate limiting amounts.

  包含重组DNA表达载体的重组宿主细胞可以用于生产有用的产品，例如在不自然产生该产品或由于缺乏前体或前体存在于限制速率的情况下产生低水平的宿主细胞中生产聚酮类化合物等产品。
• Recombinant production of novel polyketides
  申请人：THE LELAND STANFORD JUNIOR UNIVERSITY

  公开号：EP1568774A2

  公开（公告）日：2005-08-31

  Novel polyketides and novel methods of efficiently producing both new and known polyketides, using recombinant technology, are disclosed. In particular, a novel host-vector system is described which is used to produce polyketide synthases which in turn catalyze the production of a variety of polyketides.

  本文公开了新型多酮以及利用重组技术高效生产新型和已知多酮的新方法。特别是介绍了一种新型宿主-载体系统，该系统用于生产多酮合成酶，而多酮合成酶又能催化多种多酮的生产。
• A combinatorial polyketide library
  申请人：The Leland Stanford Junior University

  公开号：EP1614756A1

  公开（公告）日：2006-01-11

  Novel polyketides and novel methods of efficiently producing both new and known polyketides, using recombinant technology, are disclosed. In particular, a novel host-vector system is described which is used to produce polyketides synthases which in turn catalyze the production of a variety of polyketides.

  本文公开了新型多酮以及利用重组技术高效生产新型和已知多酮的新型方法。特别是介绍了一种新型宿主-载体系统，该系统用于生产多酮合成酶，而多酮合成酶又能催化多种多酮的生产。
• Method to prepare macrolide analogs
  申请人：——

  公开号：US20010024810A1

  公开（公告）日：2001-09-27

  Combinatorial libraries of polyketides can be obtained by suitable manipulation of a host modular polyketide synthase gene cluster such as that which encodes the PKS for erythromycin. The combinatorial library is useful as a source of pharmaceutically active compounds.

  通过对宿主模块化多酮合成酶基因簇（如编码红霉素 PKS 的基因簇）进行适当操作，可获得多酮化合物组合库。组合文库可作为药用活性化合物的来源。